We are live on ! Find out more
IPXL

Impax Laboratories, Inc.
IPXL

Delisted

IPXL was delisted on the 4th of May, 2018.

158 hedge funds and large institutions have $1.14B invested in Impax Laboratories, Inc. in 2013 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 57 increasing their positions, 57 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more call options, than puts

Call options by funds: $4.27M | Put options by funds: $1.88M

67% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 15

6% more funds holding

Funds holding: 149158 (+9)

2% more capital invested

Capital invested by funds: $1.12B → $1.14B (+$20.5M)

0% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 57

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

Holders
158
Holders Change
+9
Holders Change %
+6.04%
% of All Funds
5.12%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.03%
New
25
Increased
57
Reduced
57
Closed
15
Calls
$4.27M
Puts
$1.88M
Net Calls
+$2.39M
Net Calls Change
+$5.85M
Name Holding Trade Value Shares
Change
Change in
Stake
VOYA Investment Management
26
VOYA Investment Management
Georgia
$13.1M -$16.8K -813 -0.1%
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$11.6M +$2.46M +119,015 +27%
JP Morgan Chase
28
JP Morgan Chase
New York
$11.4M -$1.86M -90,245 -14%
Norges Bank
29
Norges Bank
Norway
$10.7M +$4.01M +194,023 +59%
TC
30
TFS Capital
Pennsylvania
$8.45M -$3.06M -148,168 -26%
Neuberger Berman Group
31
Neuberger Berman Group
New York
$8.45M +$8.52M +412,650 New
Deutsche Bank
32
Deutsche Bank
Germany
$7.88M +$4.16M +201,464 +110%
Principal Financial Group
33
Principal Financial Group
Iowa
$7.57M +$118K +5,703 +2%
AC
34
Apex Capital
California
$7.54M -$23.1M -1,116,400 -75%
TCIM
35
TIAA CREF Investment Management
New York
$7.11M -$1.29M -62,381 -15%
TCM
36
Tekla Capital Management
Massachusetts
$7.07M
Geode Capital Management
37
Geode Capital Management
Massachusetts
$6.33M +$830K +40,205 +15%
CII
38
CR Intrinsic Investors
Connecticut
$5.94M +$657K +31,815 +12%
TRSOTSOK
39
Teachers Retirement System of the State of Kentucky
Kentucky
$5.6M -$799K -38,700 -12%
BIM
40
BlackRock Investment Management
Delaware
$5.56M +$34.7K +1,682 +0.6%
TA
41
Teachers Advisors
New York
$5.42M +$82.3K +3,985 +2%
American Century Companies
42
American Century Companies
Missouri
$5.39M
PAMU
43
Pictet Asset Management (UK)
United Kingdom
$4.89M -$2.49M -120,800 -34%
OAM
44
Oxford Asset Management
United Kingdom
$4.58M -$288K -13,964 -6%
HCM
45
Highbridge Capital Management
New York
$4.31M +$4.35M +210,612 New
NFA
46
Nationwide Fund Advisors
Ohio
$3.99M +$1.7M +82,191 +73%
Federated Hermes
47
Federated Hermes
Pennsylvania
$3.96M -$77.3K -3,745 -2%
SCM
48
Sigma Capital Management
Connecticut
$3.79M +$2.17M +105,000 +131%
SCA
49
SAC Capital Advisors
Connecticut
$3.64M +$998K +48,355 +37%
CCMH
50
Cornerstone Capital Management Holdings
New York
$3.6M -$704K -34,100 -16%

IPXL Hedge Fund Activity: Q3 2013 in Review

158 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q3 2013, worth a combined $1.14B — up 1.8% from $1.12B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new IPXL positions and 15 closed out — a net gain of 10 holders — while 57 added to existing stakes and 57 trimmed.

The largest buyer was Tradewinds Global Investors, opening a new position worth an estimated $13.9M. The largest seller was Apex Capital, cutting an estimated $23.1M.

  • 158 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q3 2013, up from 149 in Q2 2013.
  • Funds reported $1.14B of Impax Laboratories, Inc. stock for Q3 2013, up 1.8% quarter-over-quarter.
  • 25 funds opened new Impax Laboratories, Inc. positions in Q3 2013 and 15 closed out, a net change of +10 holders.
  • The largest Impax Laboratories, Inc. buyer in Q3 2013 was Tradewinds Global Investors, an estimated $13.9M added.
  • The largest Impax Laboratories, Inc. seller in Q3 2013 was Apex Capital, an estimated $23.1M sold.

Based on aggregated 13F filings for Q3 2013.